<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39400461</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2470-9239</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>Epilepsia open</Title><ISOAbbreviation>Epilepsia Open</ISOAbbreviation></Journal><ArticleTitle>Safety, tolerability, and efficacy outcomes of the Investigation of Levetiracetam in Alzheimer's disease (ILiAD) study: a pilot, double-blind placebo-controlled crossover trial.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/epi4.13070</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess whether the antiseizure medication levetiracetam may improve cognition in individuals with Alzheimer's disease who have not previously experienced a seizure.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a randomized, double-blind, placebo-controlled crossover pilot study in individuals with mild-to-moderate Alzheimer's disease. Electroencephalography was performed at baseline and those with active epileptiform discharges were excluded. Eligible participants were randomized to placebo for 12 weeks or an active arm of oral levetiracetam (4 weeks up-titration to levetiracetam 500 mg twice daily, 4 weeks maintained on this dose followed by 4 weeks down-titration to nil). Participants then crossed over to the other arm. The primary outcome was change in cognitive function assessed by the Oxford Memory Task, a task sensitive to hippocampal memory binding. Secondary outcomes included tolerability, other neuropsychological scales, and general questionnaires.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Recruitment numbers were severely limited owing to restrictions from the COVID-19 pandemic at the time of the study. Eight participants completed both arms of the study (mean age 68.4 years [SD = 9.2]; 5 females [62.5%]). No participants withdrew from the study and there was no significant difference between reported side effects in the active levetiracetam or placebo arm. Measures of mood and quality of life were also not significantly different between the two arms based on participant or carer reports. In limited data analysis, there was no statistically significant difference between participants in the active levetiracetam and placebo arm on the memory task.</AbstractText><AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">This pilot study demonstrates that levetiracetam was well tolerated in individuals with Alzheimer's disease who do not have a history of seizures and has no detrimental effect on mood or quality of life. Larger studies are needed to assess whether levetiracetam may have a positive effect on cognitive function in subsets of individuals with Alzheimer's disease.</AbstractText><AbstractText Label="PLAIN LANGUAGE SUMMARY" NlmCategory="CONCLUSIONS">Abnormal electrical activity within the brain, such as is seen in seizures, might contribute to memory problems in people with dementia. We completed a clinical trial to see if an antiseizure medication, levetiracetam, could help with memory difficulties in people with Alzheimer's disease (the most common cause of dementia). In this pilot study, we could not prove whether levetiracetam helped memory function. We did show that the drug is safe and well tolerated in people with dementia who have not had a seizure. This work, therefore, offers a platform for future research exploring antiseizure medications in people with dementia.</AbstractText><CopyrightInformation>© 2024 The Author(s). Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sen</LastName><ForeName>Arjune</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8948-4763</Identifier><AffiliationInfo><Affiliation>Oxford Epilepsy Research Group, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toniolo</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1833-4995</Identifier><AffiliationInfo><Affiliation>Department of Neurology, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>Xin You</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>Oxford Epilepsy Research Group, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akinola</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Local Clinical Trials Network, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Symmonds</LastName><ForeName>Mkael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oxford Epilepsy Research Group, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurophysiology, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mura</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Trials Pharmacy, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galloway</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CPSU, Oxford Health Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallam</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>St Mary's Pharmaceutical Unit, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Jane Y C</ForeName><Initials>JYC</Initials><AffiliationInfo><Affiliation>Freeline Therapeutics, King's Court, Stevenage, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Medicine, UCB Pharma, Slough, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koychev</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Brain Sciences, Imperial College, Sir Alexander Fleming Building, South Kensington Campus, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geddes</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Gabriel Davis</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Oxford Epilepsy Research Group, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Women's Health, Women's Centre, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabi</LastName><ForeName>Younes</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital of Kiel, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maio</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frangou</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>MRC Clinical Trials Unit at UCL, Faculty of Pop Health Sciences, Institute of Clinical Trials &amp; Methodology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Love</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>MRC Clinical Trials Unit at UCL, Faculty of Pop Health Sciences, Institute of Clinical Trials &amp; Methodology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Sian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Der Putt</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Memory and Cognition Research Delivery Team, Warneford Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manohar</LastName><ForeName>Sanjay G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Neurology, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McShane</LastName><ForeName>Rupert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Husain</LastName><ForeName>Masud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cognitive Neurology Research Group, Nuffield Department Clinical Neurosciences &amp; Department of Experimental Psychology, University of Oxford, West Wing, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BRR00020 HM00.01</GrantID><Agency>United Kingdom Medical Research Council Confidence in Concept</Agency><Country /></Grant><Grant><GrantID>IIS-2015-106611</GrantID><Agency>UCB Pharma</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Epilepsia Open</MedlineTA><NlmUniqueID>101692036</NlmUniqueID><ISSNLinking>2470-9239</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Oxford Memory Test</Keyword><Keyword MajorTopicYN="N">antiseizure medications</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">epilepsy</Keyword><Keyword MajorTopicYN="N">seizure</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>10</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39400461</ArticleId><ArticleId IdType="doi">10.1002/epi4.13070</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>https://www.alz.org/alzheimers‐dementia/facts‐figures. Accessed February, 19 2024.</Citation></Reference><Reference><Citation>Martin Prince A, Wimo A, Guerchet M, Ali GC, Wu Y‐T, Prina M. World Alzheimer Report 2015 the global impact of dementia an analysis of prevalence, incidence, cost and trends. https://www.alzint.org/resource/world‐alzheimer‐report‐2015 Accessed March 31, 2024.</Citation></Reference><Reference><Citation>Hesdorffer DC, Hauser WA, Annegers JF, Kokmen E, Rocca WA. Dementia and adult‐onset unprovoked seizures. Neurology. 1996;46(3):727–730. https://doi.org/10.1212/WNL.46.3.727</Citation></Reference><Reference><Citation>Sen A, Capelli V, Husain M. Cognition and dementia in older patients with epilepsy. Brain. 2018;141(6):1592–1608. https://doi.org/10.1093/BRAIN/AWY022</Citation></Reference><Reference><Citation>Tai XY, Torzillo E, Lyall DM, Manohar S, Husain M, Sen A. Association of dementia risk with focal epilepsy and modifiable cardiovascular risk factors. JAMA Neurol. 2023;80(5):445–454. https://doi.org/10.1001/jamaneurol.2023.0339</Citation></Reference><Reference><Citation>Schnier C, Duncan S, Wilkinson T, Mbizvo GK, Chin RFM. A nationwide, retrospective, data‐linkage, cohort study of epilepsy and incident dementia. Neurology. 2020;95(12):e1686–e1693. https://doi.org/10.1212/WNL.0000000000010358</Citation></Reference><Reference><Citation>Tai XY, Bernhardt B, Thom M, Thompson P, Baxendale S, Koepp M, et al. Review: neurodegenerative processes in temporal lobe epilepsy with hippocampal sclerosis: clinical, pathological and neuroimaging evidence. Neuropathol Appl Neurobiol. 2018;44(1):70–90. https://doi.org/10.1111/nan.12458</Citation></Reference><Reference><Citation>Tai XY, Koepp M, Duncan JS, Fox N, Thompson P, Baxendale S, et al. Hyperphosphorylated tau in patients with refractory epilepsy correlates with cognitive decline: a study of temporal lobe resections. Brain. 2016;139(9):2441–2455. https://doi.org/10.1093/brain/aww187</Citation></Reference><Reference><Citation>Sen A, Thom M, Martinian L, Harding B, Cross JH, Nikolic M, et al. Pathological tau tangles localize to focal cortical dysplasia in older patients. Epilepsia. 2007;48(8):1447–1454. https://doi.org/10.1111/J.1528‐1167.2007.01107.X</Citation></Reference><Reference><Citation>Romoli M, Sen A, Parnetti L, Calabresi P, Costa C. Amyloid‐β: a potential link between epilepsy and cognitive decline. Nat Rev Neurol. 2021;17(8):469–485. https://doi.org/10.1038/s41582‐021‐00505‐9</Citation></Reference><Reference><Citation>Kanner AM, Bicchi MM. Antiseizure medications for adults with epilepsy: a review. JAMA. 2022;327(13):1269–1281. https://doi.org/10.1001/JAMA.2022.3880</Citation></Reference><Reference><Citation>Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci USA. 2012;109(42):E2895–E2903. https://doi.org/10.1073/PNAS.1121081109/‐/DCSUPPLEMENTAL</Citation></Reference><Reference><Citation>Shi JQ, Wang BR, Tian YY, Xu J, Gao L, Zhao S‐L, et al. Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice. CNS Neurosci Ther. 2013;19(11):871–881. https://doi.org/10.1111/CNS.12144</Citation></Reference><Reference><Citation>Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74(3):467–474. https://doi.org/10.1016/J.NEURON.2012.03.023</Citation></Reference><Reference><Citation>Cumbo E, Ligori LD. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease. Epilepsy Behav. 2010;17(4):461–466. https://doi.org/10.1016/J.YEBEH.2010.01.015</Citation></Reference><Reference><Citation>Sen A, Akinola M, Tai XY, Symmonds M, Jones GD, Mura S, et al. An investigation of levetiracetam in Alzheimer's disease (ILiAD): a double‐blind, placebo‐controlled, randomised crossover proof of concept study. Trials. 2021;22(1):508. https://doi.org/10.1186/S13063‐021‐05404‐4</Citation></Reference><Reference><Citation>McKhann G, Knopman D, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263–269. https://doi.org/10.1016/j.jalz.2011.03.005</Citation></Reference><Reference><Citation>Pertzov Y, Miller TD, Gorgoraptis N, Caine D, Schott JM, Butler C, et al. Binding deficits in memory following medial temporal lobe damage in patients with voltage‐gated potassium channel complex antibody‐associated limbic encephalitis. Brain. 2013;136(8):2474–2485. https://doi.org/10.1093/brain/awt129</Citation></Reference><Reference><Citation>Liang Y, Pertzov Y, Nicholas JM, Henley SMD, Crutch S, Woodward F, et al. Visual short‐term memory binding deficit in familial Alzheimer's disease. Cortex. 2016;78:150–164. https://doi.org/10.1016/j.cortex.2016.01.015</Citation></Reference><Reference><Citation>Zokaei N, Sillence A, Kienast A, Drew D, Plant O, Slavkova E, et al. Different patterns of short‐term memory deficit in Alzheimer's disease, Parkinson's disease and subjective cognitive impairment. Cortex. 2020;132:41–50. https://doi.org/10.1016/J.CORTEX.2020.06.016</Citation></Reference><Reference><Citation>Toniolo S, Maio MR, Tabi YA, Slavkova E, Plant O, Saleh Y, et al. A novel visual short‐term memory task differentiates MCI and Alzheimer's patients from healthy ageing. Alzheimers Dement. 2020;16(S6):e043006. https://doi.org/10.1002/alz.043006</Citation></Reference><Reference><Citation>Tabi YA, Maio MR, Attaallah B, Dickson S, Drew D, Idris MI, et al. Vividness of visual imagery questionnaire scores and their relationship to visual short‐term memory performance. Cortex. 2022;146:186–199. https://doi.org/10.1016/J.CORTEX.2021.10.011</Citation></Reference><Reference><Citation>Pavisic IM, Nicholas JM, Pertzov Y, O'Connor A, Liang Y, Collins JD, et al. Visual short‐term memory impairments in presymptomatic familial Alzheimer's disease: a longitudinal observational study. Neuropsychologia. 2021;162:108028. https://doi.org/10.1016/J.NEUROPSYCHOLOGIA.2021.108028</Citation></Reference><Reference><Citation>Zokaei N, Nour MM, Sillence A, Drew D, Adcock J, Stacey R, et al. Binding deficits in visual short‐term memory in patients with temporal lobe lobectomy. Hippocampus. 2019;29(2):63–67. https://doi.org/10.1002/hipo.22998</Citation></Reference><Reference><Citation>Bays PM, Catalao RFG, Husain M. The precision of visual working memory is set by allocation of a shared resource. J Vis. 2009;9(10):7. https://doi.org/10.1167/9.10.7</Citation></Reference><Reference><Citation>Tabi Y, Maio MR, Fallon S, Udale R, Dickson S, Idris MI, et al. Impact of processing demands at encoding, maintenance and retrieval in visual working memory. Cognition. 2021;214:104758. https://doi.org/10.1016/j.cognition.2021.104758</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. ‘Mini‐mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198. https://doi.org/10.1016/0022‐3956(75)90026‐6</Citation></Reference><Reference><Citation>Bucks RS, Haworth J. Bristol activities of daily living scale: a critical evaluation. Expert Rev Neurother. 2002;2(5):669–676. https://doi.org/10.1586/14737175.2.5.669</Citation></Reference><Reference><Citation>Clark CM, Ewbank DC. Performance of the dementia severity rating scale: a caregiver questionnaire for rating severity in Alzheimer disease. Alzheimer Dis Assoc Disord. 1996;10(1):31–39. https://doi.org/10.1097/00002093‐199601010‐00006</Citation></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg‐Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory. Neurology. 1994;44(12):2308. https://doi.org/10.1212/WNL.44.12.2308</Citation></Reference><Reference><Citation>https://euroqol.org/information‐and‐support/euroqol‐instruments/eq‐5d‐5l/. Accessed December 19, 2023.</Citation></Reference><Reference><Citation>Quality of life in Alzheimer's disease: patient and caregiver reports. PsycNET. Accessed December 8, 2023. https://psycnet.apa.org/record/1999‐05045‐003</Citation></Reference><Reference><Citation>Magezi D. Linear mixed‐effects models for within‐participant psychology experiments: an introductory tutorial and free, graphical user interface (LMMgui). Front Psychol. 2015;6:2. https://doi.org/10.3389/fpsyg.2015.00002</Citation></Reference><Reference><Citation>Klitgaard H, Verdru P. Levetiracetam: the first SV2A ligand for the treatment of epilepsy. Expert Opin Drug Discov. 2007;2(11):1537–1545. https://doi.org/10.1517/17460441.2.11.153</Citation></Reference><Reference><Citation>Sen A, Jette N, Husain M, Sander JW. Epilepsy in older people. Lancet. 2020;395(10225):735–748. https://doi.org/10.1016/S0140‐6736(19)33064‐8</Citation></Reference><Reference><Citation>Toniolo S, Romoli M, Sen A. Epilepsy in older persons. Neurol Clin. 2022;40(4):891–905. https://doi.org/10.1016/j.ncl.2022.03.014</Citation></Reference><Reference><Citation>Schoenberg MR, Rum RS, Osborn KE, Werz MA. A randomized, double‐blind, placebo‐controlled crossover study of the effects of levetiracetam on cognition, mood, and balance in healthy older adults. Epilepsia. 2017;58(9):1566–1574. https://doi.org/10.1111/EPI.13849</Citation></Reference><Reference><Citation>Lippa CF, Rosso A, Hepler M, Jenssen S, Pillai J, Irwin D. Levetiracetam: a practical option for seizure management in elderly patients with cognitive impairment. Am J Alzheimers Dis Other Dement. 2010;25(2):149–154. https://doi.org/10.1177/1533317508325095</Citation></Reference><Reference><Citation>Hawkins K, Dean D, Peralson G. Alternative forms of the Rey auditory verbal learning test: a review. Behav Neurol. 2004;15:99–107. https://doi.org/10.1155/2004/940191</Citation></Reference><Reference><Citation>Vossel K, Ranasinghe KG, Beagle AJ, La A, Pook KA, Castro M, et al. Effect of levetiracetam on cognition in patients with Alzheimer disease with and without epileptiform activity: a randomized clinical trial. JAMA Neurol. 2021;78(11):1345–1354. https://doi.org/10.1001/JAMANEUROL.2021.3310</Citation></Reference><Reference><Citation>Toniolo S, Sen A, Husain M. Modulation of brain hyperexcitability: potential new therapeutic approaches in Alzheimer's disease. Int J Mol Sci. 2020;21:9318. https://doi.org/10.3390/ijms21239318</Citation></Reference><Reference><Citation>Toniolo S, Zhao S, Scholcz A, Amein B, Ganse‐Dumrath A, Heslegrave AJ, et al. Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease. Alzheimers Dement. 2024;16:e12590. https://doi.org/10.1002/dad2.12590</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>